Summary of the NICE CKD guideline

This video makes reference to guidelines produced by the "National Institute for Health and Care Excellence" in the UK, also referred to as "NICE". Please note that the content on this channel reflects my professional interpretation/summary of the guidance and that I am in no way affiliated with, employed by or funded/sponsored by NICE.

My name is Fernando Florido and I am a GP in the United Kingdom. In this video I go through the NICE guidelines “Chronic kidney disease: assessment and management” or NG203, Published on 25 August 2021

There is a podcast version of this and other videos that you can access here:

Primary Care guidelines podcast:

Full NICE guideline on CKD:

CKD visual summaries:
• Websites:
o Identifying CKD:
o Managing proteinuria:
o Phosphate binders:
• Or download here:

o Managing proteinuria:

o Phosphate binders:

CKD tables- 1&2

NICE HTA guideline:

• Shorts:

SGLT2 inhibitors for adults with CKD and type 2 diabetes, see chronic kidney disease in NICE's guideline on type 2 diabetes in adults.

• Summary of guidance: CKD section of diabetes guideline 1.8.17
For adults with type 2 diabetes and CKD who are taking an ARB or an ACE inhibitor (titrated to the highest licensed dose that they can tolerate), offer an SGLT2 inhibitor (in addition to the ARB or ACE inhibitor) if:
• ACR is over 30 mg/mmol and
• they meet the criteria in the marketing authorisation (including relevant estimated glomerular filtration rate [eGFR] thresholds).
• Website: Diabetes guideline:

NICE's technology appraisal guidance on dapagliflozin for treating chronic kidney disease.

• Website:
• Or download here:

NICE's technology appraisals on sodium zirconium cyclosilicate and patiromer.

• Website:

• Or download here:
o Zirconium:

NICE's guideline on cardiovascular disease: risk assessment and reduction, including lipid modification for the use of statins in adults with CKD.

• Or download here:

MHRA safety advice on recombinant human erythropoietins:

• Website:
• Summary of advice:
Recombinant human erythropoietins: new advice for prescribing
Over-correction of haemoglobin concentration may increase the risk of death and serious cardiovascular events in patients with chronic kidney disease; it may increase the risk of thrombosis and related complications in patients with cancer.
4-variable Kidney Failure Risk Equation
• Download:

[aniskhan]

Wonderful idea to present common medical problems according to authentic and reputable NICE guidelines. Wish more topics can be uploaded with concise ideas of NICE guidelines. A great 👍🏾 job and contribution by you.

[peace.seeking]

You have no idea how amazing was that video!! Please keep up!! ❤🎉

[EzzeldinBarakat]

Thank you for this informative and updated video.

[ojushealthcare]

Many thanks, doc! you have no idea how helpful your videos are. A couple of comments on this video if I may- sections on erythropoetin, phosphate binders could have been shortened and more time spent on the CKD table, SGLT2 inhibitors, as I think they are much more relevant in GP land. Erythropoetin, phosphate binders, management of renal anaemia- I personally have not been involved in any of these as a GP, except flagging it up to the renal team. But gliflozins and the table, I use them or come across them much more often. But thanks again, and please continue making these videos- you are doing God's work!